Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Cytomegalovirus infection is a risk factor for TB disease in Infants.

Müller J, Tanner R, Matsumiya M, Snowden MA, Landry B, Satti I, Harris SA, O'Shea MK, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly Thomas ZR, Stylianou E, Naranbhai V, Mbandi SK, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Hanekom WA, Evans TG, Scriba TJ, McShane H, Fletcher HA.

JCI Insight. 2019 Nov 7. pii: 130090. doi: 10.1172/jci.insight.130090. [Epub ahead of print]

2.

Bereavement Counselling for Healthcare Workers in the Aftermath of Child Death

O’Sullivan D, Stone G, Mahomed H, O’Reilly P, Stewart P, Noonan H, Murphy AM.

Ir Med J. 2019 May 9;112(5):931. No abstract available.

PMID:
31411013
3.

Temporal trends in the prevalence of Mycobacterium tuberculosis infection in South African adolescents.

Bunyasi EW, Geldenhuys H, Mulenga H, Shenje J, Luabeya AKK, Tameris M, Nemes E, Mahomed H, Rozot V, Wood R, Scriba T, Andrews JR, Hatherill M.

Int J Tuberc Lung Dis. 2019 May 1;23(5):571-578. doi: 10.5588/ijtld.18.0283.

PMID:
31097065
4.

'Doing more with less': a qualitative investigation of perceptions of South African health service managers on implementation of health innovations.

Brooke-Sumner C, Petersen-Williams P, Kruger J, Mahomed H, Myers B.

Health Policy Plan. 2019 Mar 1;34(2):132-140. doi: 10.1093/heapol/czz017.

5.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team.

PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.

6.

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.

Schmidt BM, Tameris M, Geldenhuys H, Luabeya A, Bunyasi E, Hawkridge T, McClain JB, Mahomed H, Scriba TJ, McShane H, Hatherill M.

Trop Med Int Health. 2018 Jan;23(1):63-68. doi: 10.1111/tmi.13009. Epub 2017 Dec 4.

7.

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.

Bunyasi EW, Luabeya AKK, Tameris M, Geldenhuys H, Mulenga H, Landry BS, Scriba TJ, Schmidt BM, Hanekom WA, Mahomed H, McShane H, Hatherill M.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):778-783. doi: 10.5588/ijtld.16.0709.

8.

Training and support to improve ICD coding quality: A controlled before-and-after impact evaluation.

Dyers R, Ward G, Du Plooy S, Fourie S, Evans J, Mahomed H.

S Afr Med J. 2017 May 24;107(6):501-506. doi: 10.7196/SAMJ.2017.v107i6.12075.

PMID:
28604322
9.

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M.

Lancet Respir Med. 2017 Apr;5(4):282-290. doi: 10.1016/S2213-2600(17)30060-7. Epub 2017 Feb 16.

10.

H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.

Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, Mahomed H, Hanekom WA, Hoff ST, Ruhwald M, Kromann I, Bang P, Hatherill M, Andersen P, Scriba TJ; THYB04 study group.

Vaccine. 2017 Jan 3;35(1):132-141. doi: 10.1016/j.vaccine.2016.11.023. Epub 2016 Nov 18.

PMID:
27866772
11.

Student experiences of participating in five collaborative blended learning courses in Africa and Asia: a survey.

Atkins S, Yan W, Meragia E, Mahomed H, Rosales-Klintz S, Skinner D, Zwarenstein M; ARCADE consortium.

Glob Health Action. 2016 Oct 6;9:28145. doi: 10.3402/gha.v9.28145. eCollection 2016.

12.

Temperature Variability and Occurrence of Diarrhoea in Children under Five-Years-Old in Cape Town Metropolitan Sub-Districts.

Musengimana G, Mukinda FK, Machekano R, Mahomed H.

Int J Environ Res Public Health. 2016 Aug 29;13(9). pii: E859. doi: 10.3390/ijerph13090859.

13.

The acceptability of three vaccine injections given to infants during a single clinic visit in South Africa.

Tabana H, Dudley LD, Knight S, Cameron N, Mahomed H, Goliath C, Eggers R, Wiysonge CS.

BMC Public Health. 2016 Aug 8;16:749. doi: 10.1186/s12889-016-3324-2.

14.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

15.

BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.

Hatherill M, Scriba TJ, Udwadia ZF, Mullerpattan JB, Hawkridge A, Mahomed H, Dye C.

Clin Infect Dis. 2016 May 15;62 Suppl 3:S262-7. doi: 10.1093/cid/ciw025.

16.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

17.

A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and GC6-74 cohort study groups.

Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24.

18.

Are central hospitals ready for National Health Insurance? ICD coding quality from an electronic patient discharge record for clinicians.

Dyers RE, Evans J, Ward GA, Du Plooy S, Mahomed H.

S Afr Med J. 2016 Jan 8;106(2):181-5. doi: 10.7196/SAMJ.2016.v106i2.10079.

PMID:
26821899
19.

Climate change is catchy--but when will it really hurt?

Sweijd NA, Wright CY, Westwood A, Rouault M, Landman WA, MacKenzie ML, Nuttall JJ, Mahomed H, Cousins T, Winter K, Berhoozi F, Kalule B, Kruger P, Govender T, Minakawa N.

S Afr Med J. 2015 Nov 11;105(12):1018-23. doi: 10.7196/SAMJ.2015.v105i12.10332.

PMID:
26792158
20.

Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.

Bunyasi EW, Tameris M, Geldenhuys H, Schmidt BM, Luabeya AK, Mulenga H, Scriba TJ, Hanekom WA, Mahomed H, McShane H, Hatherill M.

PLoS One. 2015 Nov 10;10(11):e0141623. doi: 10.1371/journal.pone.0141623. eCollection 2015.

21.

T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents.

Seshadri C, Lin L, Scriba TJ, Peterson G, Freidrich D, Frahm N, DeRosa SC, Moody DB, Prandi J, Gilleron M, Mahomed H, Jiang W, Finak G, Hanekom WA, Gottardo R, McElrath MJ, Hawn TR.

J Immunol. 2015 Nov 15;195(10):4595-603. doi: 10.4049/jimmunol.1501285. Epub 2015 Oct 14.

22.

Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.

Luabeya KK, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, Toefey A, Scriba TJ, Hussey G, Mahomed H, McShane H, Landry B, Hanekom WA, Hatherill M.

Pediatr Infect Dis J. 2015 Nov;34(11):1218-22. doi: 10.1097/INF.0000000000000874.

23.

The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children.

Mulenga H, Tameris MD, Luabeya KK, Geldenhuys H, Scriba TJ, Hussey GD, Mahomed H, Landry BS, Hanekom WA, McShane H, Hatherill M.

Pediatr Infect Dis J. 2015 Nov;34(11):1157-62. doi: 10.1097/INF.0000000000000847.

24.

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, Andersen P, Scriba TJ; H56-032 Trial Study Group, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, Hughes EJ, Bang P, Snowden MA, McClain B, Hussey GD.

Vaccine. 2015 Aug 7;33(33):4130-40. doi: 10.1016/j.vaccine.2015.06.051. Epub 2015 Jun 19.

PMID:
26095509
25.

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, Bennett S, Andersen P, Kromann I, Hoff ST, Hanekom WA, Mahomed H, Hatherill M, Scriba TJ; H4:IC31 Trial Study Group, van Rooyen M, Bruce McClain J, Ryall R, de Bruyn G; H4:IC31 Trial Study Groupa.

Vaccine. 2015 Jul 9;33(30):3592-9. doi: 10.1016/j.vaccine.2015.05.036. Epub 2015 Jun 3.

PMID:
26048780
26.

COMPASS identifies T-cell subsets correlated with clinical outcomes.

Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, C De Rosa S, McElrath MJ, Gottardo R.

Nat Biotechnol. 2015 Jun;33(6):610-6. doi: 10.1038/nbt.3187. Epub 2015 May 25.

27.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.

28.

The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.

Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ.

Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91. doi: 10.1164/rccm.201409-1704OC.

29.

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.

Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.

30.

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.

Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA; 018-402 Clinical Lab study team, Mansoor N, Hughes J, de Kock M, Whatney W, Africa H, Krohn C, Veldsman A, Kany AL, Douoguih M, Pau MG, Hendriks J, McClainc B, Benko J, Snowden MA, Hokey DA.

Vaccine. 2014 Oct 14;32(45):5908-17. doi: 10.1016/j.vaccine.2014.09.001. Epub 2014 Sep 10.

PMID:
25218194
31.

Time to symptom resolution in young children treated for pulmonary tuberculosis.

Mpofu N, Moyo S, Mulenga H, Luabeya KK, Tameris M, Geldenhuys H, Hussey G, Scriba T, Hanekom W, Mahomed H, Hatherill M.

Pediatr Infect Dis J. 2014 Dec;33(12):1226-30. doi: 10.1097/INF.0000000000000523.

32.

A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community.

Geldenhuys HD, Whitelaw A, Tameris MD, Van As D, Luabeya KK, Mahomed H, Hussey G, Hanekom WA, Hatherill M.

Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2259-66. doi: 10.1007/s10096-014-2198-4. Epub 2014 Jul 15.

33.

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.

Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314.

34.

Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.

Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A, Tanner R, O'Shea MK, Manjaly Thomas ZR, Tameris M, Mahomed H, Scriba TJ, Hanekom WA, Fletcher HA, McShane H.

Clin Vaccine Immunol. 2014 Jul;21(7):1005-11. doi: 10.1128/CVI.00128-14. Epub 2014 May 14.

35.

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ.

PLoS One. 2014 Feb 3;9(2):e87340. doi: 10.1371/journal.pone.0087340. eCollection 2014.

36.

The effect of carbohydrate ingestion on performance during a simulated soccer match.

Goedecke JH, White NJ, Chicktay W, Mahomed H, Durandt J, Lambert MI.

Nutrients. 2013 Dec 16;5(12):5193-204. doi: 10.3390/nu5125193.

37.

Justice through the J88: the doctor's role in the criminal justice system.

Rowe K, Botha H, Mahomed H, Schlemmer A.

S Afr Med J. 2013 Jul;103(7):437. No abstract available.

PMID:
23946952
38.

Tuberculosis vaccine trials - Authors' reply.

Tameris M, Hatherill M, Mahomed H, McShane H.

Lancet. 2013 Jun 29;381(9885):2254. doi: 10.1016/S0140-6736(13)61483-X. No abstract available.

PMID:
23809562
39.

Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.

Dintwe OB, Day CL, Smit E, Nemes E, Gray C, Tameris M, McShane H, Mahomed H, Hanekom WA, Scriba TJ.

Eur J Immunol. 2013 Sep;43(9):2409-20. doi: 10.1002/eji.201343454. Epub 2013 Jul 8.

40.

Reply: Risk of tuberculosis among QuantiFERON converters and nonconverters.

Mahomed H, Machingaidze S, Hanekom WA, Hatherill M, Verver S.

Am J Respir Crit Care Med. 2013 May 15;187(10):1140-1. doi: 10.1164/rccm.201301-0160LE. No abstract available.

PMID:
23675721
41.

TB incidence in an adolescent cohort in South Africa.

Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, Hanekom WA, Verver S, Hussey GD.

PLoS One. 2013;8(3):e59652. doi: 10.1371/journal.pone.0059652. Epub 2013 Mar 22.

42.

Screening for TB in high school adolescents in a high burden setting in South Africa.

Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, Hanekom WA, Verver S, Hussey GD.

Tuberculosis (Edinb). 2013 May;93(3):357-62. doi: 10.1016/j.tube.2013.02.007. Epub 2013 Mar 7.

PMID:
23477938
43.

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.

Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill M, Mahomed H.

Tuberculosis (Edinb). 2013 Mar;93(2):143-9. doi: 10.1016/j.tube.2013.01.003. Epub 2013 Feb 12.

44.

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team.

Lancet. 2013 Mar 23;381(9871):1021-8.

45.

Knowledge and acceptability of patient-specific infection control measures for pulmonary tuberculosis.

Gonzalez-Angulo Y, Geldenhuys H, Van As D, Buckerfield N, Shea J, Mahomed H, Hanekom W, Hatherill M.

Am J Infect Control. 2013 Aug;41(8):717-22. doi: 10.1016/j.ajic.2012.10.003. Epub 2013 Feb 1.

PMID:
23375576
46.

Analysis of time to regulatory and ethical approval of SATVI TB vaccine trials in South Africa.

Geldenhuys H, Veldsman A, Tameris M, Luabeya A, Hanekom W, Mahomed H, Hatherill M.

S Afr Med J. 2012 Nov 8;103(2):85-9. doi: 10.7196/samj.6390.

PMID:
23374302
47.

Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.

Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. doi: 10.1164/rccm.201208-1385OC.

48.

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.

Rustomjee R, McClain B, Brennan MJ, McLeod R, Chetty-Makkan CM, McShane H, Hanekom W, Steel G, Mahomed H, Ginsberg AM, Shea J, Lockhart S, Self S, Churchyard GJ.

Tuberculosis (Edinb). 2013 Mar;93(2):136-42. doi: 10.1016/j.tube.2012.11.005. Epub 2012 Dec 23.

PMID:
23266259
49.

Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents.

Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H.

Am J Respir Crit Care Med. 2012 Nov 15;186(10):1051-6. doi: 10.1164/rccm.201206-1134OC. Epub 2012 Sep 6.

PMID:
22955316
50.

Vaccine trials in the developing world: operational lessons learnt from a phase IV poliomyelitis vaccine trial in South Africa.

Geldenhuys H, Waggie Z, Jacks M, Geldenhuys M, Traut L, Tameris M, Hatherill M, Hanekom WA, Sutter R, Hussey G, Mahomed H.

Vaccine. 2012 Aug 31;30(40):5839-43. doi: 10.1016/j.vaccine.2012.07.026. Epub 2012 Jul 24.

PMID:
22835741

Supplemental Content

Loading ...
Support Center